Home Cart Sign in  
Chemical Structure| 108612-54-0 Chemical Structure| 108612-54-0

Structure of 108612-54-0

Chemical Structure| 108612-54-0

tert-Butyl methyl(piperidin-4-yl)carbamate

CAS No.: 108612-54-0

4.5 *For Research Use Only !

Cat. No.: A191686 Purity: 97%

Change View

Size Price

US Stock

Global Stock

In Stock
250mg łÇʶÊÊ Inquiry Inquiry
1g łÇ˶ÊÊ Inquiry Inquiry
5g łË˶ÊÊ Inquiry Inquiry
10g łÍʶÊÊ Inquiry Inquiry
25g łóͶÊÊ Inquiry Inquiry
100g ł§§ÿ¶ÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • 250mg

    łÇʶÊÊ

  • 1g

    łÇ˶ÊÊ

  • 5g

    łË˶ÊÊ

  • 10g

    łÍʶÊÊ

  • 25g

    łóͶÊÊ

  • 100g

    ł§§ÿ¶ÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 108612-54-0 ]

CAS No. :108612-54-0
Formula : C11H22N2O2
M.W : 214.30
SMILES Code : O=C(OC(C)(C)C)N(C)C1CCNCC1
MDL No. :MFCD02683051
InChI Key :DJJOYDXRUBOZON-UHFFFAOYSA-N
Pubchem ID :2756806

Safety of [ 108612-54-0 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 108612-54-0 ] Show Less

Physicochemical Properties

Num. heavy atoms 15
Num. arom. heavy atoms 0
Fraction Csp3 0.91
Num. rotatable bonds 4
Num. H-bond acceptors 3.0
Num. H-bond donors 1.0
Molar Refractivity 64.2
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

41.57 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.77
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.24
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.22
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.15
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.76
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.43

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.69
Solubility 4.42 mg/ml ; 0.0206 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.71
Solubility 4.17 mg/ml ; 0.0195 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.72
Solubility 4.08 mg/ml ; 0.0191 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.73 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.2

Application In Synthesis of [ 108612-54-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 108612-54-0 ]

[ 108612-54-0 ] Synthesis Path-Downstream   1~2

  • 1
  • [ 34584-69-5 ]
  • [ 108612-54-0 ]
  • [ 1227070-23-6 ]
YieldReaction ConditionsOperation in experiment
65% With potassium carbonate; In dimethyl sulfoxide; at 120℃; for 48h; Preparation 1 tert-Butyl l-(6-chloro-4,5-dimethylpyridazin-3-yl)piperidin-4-yl(methyl)carbamate; Heat a mixture of <strong>[34584-69-5]3,6-dichloro-4,5-dimethylpyridazine</strong> (11.0 g, 62.1 mmol), tert- butyl methyl(piperidin-4-yl)carbamate (23.3 g, 109 mmol), and powdered K2CO3 (17.2 g, 124 mmol) in DMSO (310 mL) at 120 0C for 2 d. Cool the reaction mixture, dilute with H2O, and filter off the solid. Rinse the solid with H2O, and dry under vacuum at 45 0C. Dissolve the solid in CH2CI2, and pass the solution through a pad of silica gel, eluting with CH2CI2. Concentrate the organic layer under reduced pressure to obtain the title compound as a yellow solid (14.3 g, 65%). ES/MS m/z (35Cl) 355.0 (M+l).
30% With N-ethyl-N,N-diisopropylamine; In 1-methyl-pyrrolidin-2-one; at 150℃; for 5h; tert-Butyl piperidin-4-ylmethylcarbamate (3.8i g, i 7.8mmol), <strong>[34584-69-5]3,6-dichloro-4,5-dimethyl-pyridazine</strong> (3.Og, i7.Ommol), NMP (i4mL) and N,N-Diisopropylethylamine (4.43mL, 25.4mmol) were added to a round bottom flask and heated to iSO C for 5 h. The mixture was partitioned between EtOAc (i 00 mL) and i M Na2003 aq. (50 mL). The organic layer was washed with i M Na2003 aq. (5OmL),water (2 x 7OmL), brine (70 mL), before passage through a hydrophobic frit and concentrated in vacuo to give an orange/brown solid. The crude material was purified by silica flash chromatography using 0% EtOAc in heptane with tn ethylamine i% with a gradient increasing to 30% ethyl actetate. Fractions containing product were combined and concentrated in vacuo to afford tert-butyl N-[i -(6-chloro-4,5-dimethyl-pyridazin-3-yl)-4-piperidyl]-N-methyl-carbamate(i .8g,5.i mmol, 30% yield).1H NMR (400MHz, ODd3) s/ppm: 4.34-3.84 (m, 2H), 3.56-3.47 (m(br), 2H), 3.00 (t(br), Ji2.OHz,2H), 2.78 (s, 3H), 2.3i (s, 3H), 2.25 (s, 3H), i .93-i .80 (m, 2H), i .78-i .7i (m(br), 2H), i .47 (s, 9H).MS Method 2: RT: i .88 mi m/z 355.9 [M÷H]÷
  • 2
  • [ 131747-63-2 ]
  • [ 108612-54-0 ]
  • tert-butyl (1-((4-bromopyridin-2-yl)methyl)piperidin-4-yl)(methyl)carbamate [ No CAS ]
YieldReaction ConditionsOperation in experiment
56% With sodium cyanoborohydride; acetic acid; In methanol; at 20℃; for 16h; 4-Bromopicolinaldehyde (500 mg, 2.69 mmol) and ierf-butyl methyl(piperidin-4- yl)carbamate (634 mg, 2.96 mmol) were dissolved in 50 mL methanol. Sodium cyanoborohydride (254 mg, 4.04 mmol) and four drops of acetic acid were added and the reaction mixture was stirred at room temperature for 16 h. The solvent was evaporated and the crude was re-dissolved in dichloromethane, washed with sodium carbonate and sodium hydroxide. The organics were dried over sodium sulphate, filtered and concentrated under reduced pressure. The yellow oil obtained was purified by reverse phase using SP1® Purification System to give 573 mg (56percent yield) of the title compound. LRMS (m/z): 385 (M+1 )+.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 108612-54-0 ]

Amides

Chemical Structure| 147539-41-1

A168393 [147539-41-1]

tert-Butyl 4-(methylamino)piperidine-1-carboxylate

Similarity: 1.00

Chemical Structure| 301225-58-1

A172639 [301225-58-1]

tert-Butyl 4-(propylamino)piperidine-1-carboxylate

Similarity: 1.00

Chemical Structure| 534595-51-2

A915900 [534595-51-2]

1-Boc-4-(isopropylamino)piperidine

Similarity: 1.00

Chemical Structure| 207405-68-3

A114194 [207405-68-3]

tert-Butyl endo-3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate

Similarity: 0.98

Chemical Structure| 744183-20-8

A123720 [744183-20-8]

tert-Butyl exo-3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate

Similarity: 0.98

Amines

Chemical Structure| 147539-41-1

A168393 [147539-41-1]

tert-Butyl 4-(methylamino)piperidine-1-carboxylate

Similarity: 1.00

Chemical Structure| 301225-58-1

A172639 [301225-58-1]

tert-Butyl 4-(propylamino)piperidine-1-carboxylate

Similarity: 1.00

Chemical Structure| 534595-51-2

A915900 [534595-51-2]

1-Boc-4-(isopropylamino)piperidine

Similarity: 1.00

Chemical Structure| 207405-68-3

A114194 [207405-68-3]

tert-Butyl endo-3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate

Similarity: 0.98

Chemical Structure| 744183-20-8

A123720 [744183-20-8]

tert-Butyl exo-3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate

Similarity: 0.98

Related Parent Nucleus of
[ 108612-54-0 ]

Piperidines

Chemical Structure| 147539-41-1

A168393 [147539-41-1]

tert-Butyl 4-(methylamino)piperidine-1-carboxylate

Similarity: 1.00

Chemical Structure| 301225-58-1

A172639 [301225-58-1]

tert-Butyl 4-(propylamino)piperidine-1-carboxylate

Similarity: 1.00

Chemical Structure| 534595-51-2

A915900 [534595-51-2]

1-Boc-4-(isopropylamino)piperidine

Similarity: 1.00

Chemical Structure| 87120-72-7

A143361 [87120-72-7]

tert-Butyl 4-aminopiperidine-1-carboxylate

Similarity: 0.98

Chemical Structure| 189819-75-8

A105977 [189819-75-8]

tert-Butyl 4-aminopiperidine-1-carboxylate hydrochloride

Similarity: 0.96